FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.'s Wishes The New York Times In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for FDA to weigh easing limits on unproven peptides promoted by RFK Jr. Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law